NASDAQ$GH
Guardant Health Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Guardant Health reported Q2 2025 revenue of $232.1 million with a net loss of $99.9 million.
Guardant Health Inc. achieved total revenue of $232.1 million in Q2 2025, driven by growth in oncology testing and the launch of its Shield screening test. The company reported a net loss of $99.9 million and continued investment in R&D and commercial expansion. Cash and cash equivalents stood at $629.1 million at quarter end.
- Q2 2025 revenue reached $232.1 million, up 31% year-over-year, with oncology contributing $158.7 million.
- Shield screening test generated $14.8 million in its first full quarter post-FDA approval and Medicare coverage.
- Net loss narrowed slightly to $99.9 million from $102.6 million in Q2 2024 amid higher operating expenses.
- US revenue accounted for $216.7 million, or 93% of total, with international revenue at $15.4 million.
Headline financials
Revenue & EPS history
Guardant Health · Revenue · Quarterly
$232M
Revenue by segment
Guardant Health · $232M total across 4 segments · Q2 2025
- Oncology$159M—68.4%
- Biopharma and data$56M—24.1%
- Screening$14.8M—6.4%
- Licensing and other$2.57M—1.1%
Forward guidance
The company continues to advance its Shield platform for multi-cancer detection and lung cancer screening with ongoing clinical studies.
Tailwinds
- FDA approval and Medicare coverage secured for Shield colorectal cancer screening test.
- National Comprehensive Cancer Network included Shield in updated guidelines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+3.8%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+3.9%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+41.3%
Q4 2018
Best reaction
-30.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +4.3% | +6.6% | +36.1% | |
| Q4 2025 | -3.0% | -10.4% | -19.9% | |
| Q3 2025 | +28.5% | +35.8% | +50.0% | |
| Q1 2025 | +3.5% | -11.2% | -14.0% | |
| Q4 2024 | -9.6% | -8.9% | -2.7% | |
| Q3 2024 | +21.6% | +24.8% | +56.8% | |
| Q2 2024 | -5.9% | -5.3% | -26.2% | |
| Q1 2024 | +20.0% | +32.7% | +53.8% | |
| Q4 2023 | -14.3% | -13.8% | -23.9% | |
| Q3 2023 | -8.5% | -24.7% | -10.2% | |
| Q2 2023 | +4.6% | +1.9% | -3.1% | |
| Q1 2023 | +17.2% | +12.1% | +38.5% | |
| Q4 2022 | +4.4% | +11.7% | -12.6% | |
| Q3 2022 | +3.3% | -3.1% | +17.5% | |
| Q2 2022 | +1.6% | -6.0% | +2.0% | |
| Q1 2022 | -30.0% | -44.3% | -32.3% | |
| Q4 2021 | +6.0% | +7.0% | -4.3% | |
| Q3 2021 | -3.8% | -5.8% | -20.8% | |
| Q2 2021 | +0.2% | -7.7% | +15.7% | |
| Q1 2021 | -3.1% | -14.0% | -15.8% | |
| Q4 2020 | -6.7% | -5.0% | -15.3% | |
| Q3 2020 | -0.4% | -1.1% | +9.0% | |
| Q2 2020 | +0.6% | -4.0% | +6.8% | |
| Q1 2020 | +9.0% | +19.6% | +2.9% | |
| Q4 2019 | -14.7% | -2.1% | -25.9% | |
| Q3 2019 | +11.2% | +13.8% | +14.4% | |
| Q2 2019 | +25.8% | +18.2% | -5.2% | |
| Q1 2019 | +17.4% | +12.0% | +40.3% | |
| Q4 2018 | +41.3% | +46.6% | +7.9% | |
| Q3 2018 | -6.7% | +3.1% | -2.7% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro